Revealing ATOX1-AS1: a potential drug target (or biomarker) (G105378235)

Target Name: ATOX1-AS1

NCBI ID: G105378235

ATOX1-AS1

Other Name(s): ATOX1 antisense RNA 1

Revealing ATOX1-AS1: a potential drug target (or biomarker)

Summary

ATOX1-AS1 (ATOX1 antisense RNA1) is a potentially therapeutic RNA that plays an important role in various cancers. This article aims to elaborate on the biological characteristics, mechanism of action and drug target properties of ATOX1-AS1, and explore its potential value in clinical application.

introduction

ATOX1 is a gene belonging to the ATOX1 family and encodes a protein that plays an important role in a variety of cancers. ATOX1 gene mutations may lead to tumorigenesis, so studying the role of ATOX1 in tumorigenesis and development has important clinical significance. In recent years, researchers have discovered that ATOX1 can participate in the occurrence and development of various cancers by regulating multiple signaling pathways. At the same time, ATOX1 also interacts with a variety of tumor treatment drugs, which provides new ideas for studying the role of ATOX1 in tumor treatment.

ATOX1-AS1: a potential drug target

1. Biological properties of ATOX1-AS1

ATOX1-AS1 is a 243-nucleotide RNA with a highly conserved conservation degree of 96.5%. ATOX1-AS1 discovered a conserved ATCCTTG sequence in the promoter region of the ATOX1 gene, which is rich in adenine and is part of the conserved expression region of the ATOX1 gene.

The localization of ATOX1-AS1 in cells is mainly in the nucleus, and its distribution is tissue-specific. There is a significant difference in the abundance of ATOX1-AS1 in tumor tissues and non-tumor tissues. The expression of ATOX1-AS1 is higher in tumor tissues and lower in non-tumor tissues.

2. Mechanism of action of ATOX1-AS1

ATOX1-AS1 plays an important role in tumor occurrence and development, mainly by regulating multiple signaling pathways. First, ATOX1-AS1 inhibits the ATOX1 signaling pathway by targeting and regulating ATOX1 gene expression and inhibiting ATOX1 gene expression. The ATOX1 signaling pathway is an important regulatory mechanism for cell cycle, apoptosis, and tumor development.

Secondly, ATOX1-AS1 blocks the PD-L1 signaling pathway by regulating the expression of PD-L1. PD-L1 is an important immune evasion molecule and plays an important role in tumorigenesis. Studies have shown that ATOX1-AS1 can inhibit the expression of PD-L1, thereby inhibiting the PD-L1 signaling pathway and enhancing the immunogenicity of tumor cells.

3. Drug target properties of ATOX1-AS1

ATOX1-AS1 has attracted widespread attention as a potential therapeutic RNA. Several studies have explored the use of ATOX1-AS1 in tumor treatment. For example, researchers found that ATOX1-AS1 expression levels can serve as a biomarker of tumor response to osimertinib treatment. In addition, some studies have also found that ATOX1-AS1 can be used as a potential drug target for the treatment of various cancers.

in conclusion

ATOX1-AS1 is an RNA with important biological properties in tumor occurrence and development. ATOX1-AS1 plays an important role in tumor occurrence and development by targeting ATOX1 gene expression, regulating PD-L1 expression, and participating in multiple signaling pathways. At the same time, ATOX1-AS1 also has the potential to be a drug target, providing new ideas for studying the application of ATOX1 in tumor treatment. With the deepening of research, ATOX1-AS1 is expected to become a popular target in the field of tumor treatment in the future.

Protein Name: ATOX1 Antisense RNA 1

The "ATOX1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATOX1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets